Supporting equitable booster strategies: one-year real-world immunogenicity data in people with HIV (PWH) receiving different variant-adapted COVID-19 vaccines
Overall, mRNA boosters provided a stronger early humoral response, while Nuvaxovid may promote more sustained T-cell immunity. Both maintained robust responses over 12 months, supporting their use in people with HIV (PWH). Given its thermostability and accessibility, Nuvaxovid is a practical alternative when mRNA vaccines are unavailable or contraindicated.
Authors
- Francesca Colavita (ORCID: https://orcid.org/0000-0003-0640-8667)
- Simona Gili
- Alessandro Cozzi Lepri (ORCID: https://orcid.org/0000-0001-7305-4382)
- Davide Mariotti (ORCID: https://orcid.org/0000-0002-7698-1103)
- Rozenn Esvan (ORCID: https://orcid.org/0000-0001-6127-0045)
- Fabrizio Maggi (ORCID: https://orcid.org/0000-0001-7489-5271)
- Flavia Cristofanelli
- Alessandra Vergori (ORCID: https://orcid.org/0000-0001-6944-0686)
- Valentina Mazzotta (ORCID: https://orcid.org/0000-0002-0240-7504)
- Eleonora Cimini (ORCID: https://orcid.org/0000-0002-2659-0868)
- Giulia Matusali (ORCID: https://orcid.org/0000-0002-2948-4243)
- Andrea Antinori
Institutions
- Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- University College London (GB)
Publication Details
- Journal
- International Journal of Infectious Diseases
- Published
- 2025-11-08
- DOI
- https://doi.org/10.1016/j.ijid.2025.108189
- Citations
- 1
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 1.40